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The Canadian Sarcoma Group (CSG) held itsthird national
workshopª Sarcomas:MolecularMarkersto Therapeuticsº,
at the Colony Hotel,Toronto, 26-27 February 2000.The
meeting was attended by approximately 50 speakers and
participants (Appendix 1) representing a broad range of
disciplines including scientists, medical and radiation
oncologists, pathologists, radiologists and community
representatives. The format of the Workshop encouraged
audience participation and there were lively discussions
within each of the four sessions.
The overall objectives of the Workshop were to do the
groundworkfor a ® ve year program of scienti® c and clinical
trials activity for the CSG. Speci® c aims of each session are
outlined in their titles.
SESSION 1
DEVELOPMENT OF NEW MOLECULAR
MARKERS CORRELATINGWITH CLINICAL
OUTCOMES IN SOFTTISSUE SARCOMA
(STS)
MODERATOR: IRENE ANDRULIS
SARCOMA BIOLOGY - FROM GENETICS
TO SIGNALTRANSDUCTION
Poul Sorensen,Vancouver
Dr Sorensen reviewed some of his work demonstrating the
presence of a translocation12,15 in congenital ® brosar-
coma, which distinguishes it from ® bromatosis and
low-grade adult ® brosarcomas. This translocation causes
the formation of chimeric oncoprotein, ETV6-NTRK3,
which is a tyrosine kinase. Expression of this protein in
NIH3T3 cells is oncogenic, and transformation requires
both the ETV6 helix-loop-helix dimerization domain and
the NTRK3 protein tyrosine kinase domain. Dr. Sorensen
has created a mouse model, showing that incorporation of
this oncoprotein in 3T3 cells renders them tumorigenic.
MICRO-ARRAY TECHNIQUES IN
SARCOMA
JayWunder,Toronto
Dr Wunder explained the potential of micro-array
techniques in assessing global patterns of gene expression.
Micro-array analysis offers the potential to simultaneously
analyze mRNA levels of hundreds or thousands of genes.
One of the goalsis to identifyª geneticpro® lesº or ª signature
patternsº of gene expression for speci® c tumors that might
help to better classify them, predict outcome and response
to therapy. This might also provide new gene targets for
therapy. He brie¯ y described an NIH Consortium grant
application involving six centresincludingToronto,brought
together under the umbrella of the Connective Tissue
Oncology Society. If funded, this grant would provide core
facilities for tissue banks, pathology review, and bioinfor-
matics and would include three main scienti® c projects
examining the molecular pro® les of liposarcoma,
leiomyosarcoma/gastrointestinal stromal tumors (GIST)
and malignant ® brous histiocytoma. He described some of
the proposed Toronto-Rizzoli Institute work on liposar-
coma, and ® nally outlined some of the challenges that arise
in using these techniques.
BIOLOGIC RESPONSE MODIFIERS IN
RHABDOMYOSARCOMA
David Malkin,Toronto
Dr Malkin discussed the childhood rhabdomyosarcomas
which share a common defect in myogenic differentiation.
MyoD is expressed but is non-functional in tumors.
Embryonal and alveolar types of rhabdomyosarcoma each
show different translocations. He described some of his
scienti® c work on the characteristics of MyoD. He went on
to describe a series of experiments using retinoic acid,
which is a differentiating agent in acute promyelocytic
leukemia and neuroblastoma. He has shown that retinoic
acid can cause growth arrest and morphological differentia-
tion in some rhabdomyosarcoma cell lines. He plans a
further series of experiments which he hopes will lead into
some parallel clinical studies.
MOLECULAR AND CYTOGENETIC
APPROACHES TO IMPROVED OUTCOME
ASSESSMENT IN SARCOMAS
Jeremy Squire,Toronto
Ewing’s sarcoma (ES) is characterized by chromosomal
rearrangementsinvolving 22q12 which alter the EWS gene.
In addition to these consistent aberrations, both numerical
and structural aberrations have beenreported:namelygains
of chromosomes 8 and 12, the unbalanced translocation
t(1;16), and deletions at the short arm of chromosome 1.
To evaluate the frequency and to study the prognostic
implications of some of these aberrations in children, Dr.
Squire’s group analyzed tumor specimens from 26ES pedi-
atric patients by classical cytogenetics and/or interphase
¯ uorescence in situ hybridization (FISH) and compared
these data with clinical parameters by interphase FISH
analysis. Gains of chromosomes 8 and 12 were detected in
48% (10/21) and 38% (6/16) of the tumors respectively,
and this was not signi® cant with outcome.Statistical analysis
revealed that the presence of a complex karyotype (ie. two
or more structurally rearranged chromosomes) was associ-
ated with an unfavourable outcome when compared to ES
tumors with simpler karyotypes (p=0.0034 was an
independent prognostic value as an unfavourable marker).
EXPERIMENTAL STUDIES OF THE
EFFECTS OF RADIATION ONWOUND
HEALING AND FIBROSIS
Richard Hill,Toronto
Combined radiation and surgery has proven to be highly
successful in producing local control of several malignan-
cies including STS. However, substantial long term
morbidity may occur as a result of two complications: poor
wound healing or post-radiation ® brosis. The NCIC-
CTG/CSG SR2 trial demonstrated that STS patients
receiving preoperative radiation had a 35% risk of
developing wound healing complications. Tissue ® brob-
lasts play an important role in wound healing as well as the
development of ® brosis. Dr. Hill’s group has shown that
poor wound healing in rats caused by preoperative radia-
tion can be partially reversed by transplanted autogenous
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been previously irradiated. Dr. Hill is currently examining
the radiosensitivity of skin ® broblasts from patients treated
with preoperative irradiation for STS.Five of the 12patients
studied to date demonstrated wound healing complica-
tions. A clonogenic assay, with irradiation given at a low
dose rate (LDR - 2.5 cGy/min), is used and for most
patients at least two separate isolates of ® broblasts from
their biopsies have been studied to determine the consist-
ency of the measurements.The ® broblasts were character-
ized into three groups (sensitive, intermediate and normal)
in relation to their radiosensitivity (dose required to give
1% survival).For the patients with woundhealing problems
60% (3/5) had sensitive or intermediate sensitivity ® brob-
last vs 28 % (2/7) for patients without wound healing
problems. A further 12 samples from a population of
patients treated with preoperative irradiation for STS (7
with wound healing complications and 5 without)are under
study. A study of TGF beta levels has been initiated since
this cytokine plays an important role in wound healing and
recent studies have reported that plasma levels correlate
with the development of radiation-induced ® brosis.
PANEL DISCUSSION WITH AUDIENCE
PARTICIPATION
The ® rst part of the discussion focused on molecular
mechanisms that might be targets for therapy, including
IGF-1, IGF-2, p53,MDR,and some of the techniques that
might be used to detectalterations.Micro-array techniques
may be able to identify additional targets,but issues such as
quality of tissue and the in¯ uence of heterogeneity within
the tumor,or hypoxia were also emphasized.In response to
a question as to whether any markers could currently be
used prospectively in adult STS, Dr Andrulis emphasized
the need for proper epidemiological studies such as those
that had been performed in breast cancer. Dr Malkin
commented on the fact that, in U.S. pediatric trials, 23
gene/proteins are being analyzed by multiple laboratories.
Samples are obtained from all patients entered into pedi-
atric clinical trials through the Childrens Oncology Group.
There was some additional discussion around prediction of
tumor radiosensitivity.
The discussion then focused on the CSG tumor bank/
database. In response to a query about how representative
this might be for adult STS across the country, it was
acknowledged that there is a bias to extremity sarcomas
and primary tumors because of the specialties of the
contributingsurgeons.Dr Bell commentedthat the relative
numbers could be compared with those recorded in the
Ontario Cancer Registry. Dr O’Sullivan pointed out that
although the project could be broadened by involving other
surgeons, there may be logistic issues.
With respect to tumor banks, Dr Sorensen commented
that handling of specimens may be important and advocated
looking into new methods of culture, as well as freezing
specimens. He felt it would be useful to have a bank of
mouse human tumor xenograft models in which one could
examine therapeutic manoeuvres.There was some discus-
sion on the various mouse models that might be useful in
this setting.
The ® nal segment of the discussion focused on the best
use of the CSG tumor bank/database to improve treat-
ments. Dr Eisenhauer pointed out this issue would be
discussed in the afternoon session. DrAndrulis emphasized
the importanceof the ® rst step of identifyingsuitable targets,
and it was acknowledged the studies will be driven by the
expertise of individual Canadian investigators and the types
of material available in the bank. Dr Bell pointed out that
this meeting was timely as it is only now that the CSG has
a useful tumor bank with more than 800 specimens and
follow-up clinical data.There was some additional discus-
sion around technical issues relating to the bank.
SESSION 2
INVESTIGATIONAL NEW DRUG
OPPORTUNITIES IN SOFTTISSUE
SARCOMA
MODERATOR: VIVIEN BRAMWELL
NEW DRUGS OF POTENTIAL INTEREST IN
SARCOMAS - EUROPEAN PERSPECTIVE
Will Steward, Leicester,UK
Dr Steward noted that the EORTC has performed two
phase II studies/year for 20 years examining new agents,
new schedules or modi® ed doses of various drugs, but
despite all this activity there remain only two active drugs
in adult STS.There is a real need to maintain enthusiasm
to continue investigational new drug studies.The EORTC
will conduct a phase II study of irinotecan in GIST. Ecti-
nascidin (ET-743), a compound derived from a marine
organism that has broad activity in animal models including
sarcoma, is in phase II study by the EORTC. Dr Steward
described a number of interesting drugs under develop-
ment in the UK. Most of these are in phase I evaluation
with phase II studies planned in STS. An anthraquinone
di-N-oxide (AQ4N), is a topo-isomerase II inhibitor. It
enhances the effects of cisplatin and cyclophosphamide,
and has synergy with radiotherapy. BBR 3464 is a novel
trinuclear platinum compound. Combretastatin A4
phosphate shows potent selective toxicity for tumor associ-
ated endothelium. Finally, he described PTK 787 an
aminophenothalazine which causes dose dependentinhibi-
tion of VEGF-R tyosine kinase and PDGF-R tyrosine
kinase.This also is in phase I study,withassociated dynamic
MR imaging of tumor blood ¯ ow. Phase II studies are
planned in soft tissue and osteosarcomas, which are high
expressors of VEGF.
TARGETING PEDIATRIC SARCOMAS FOR
IMMUNETHERAPY
Crystal Mackall,NCI,US
Unfortunately Dr Mackall, despite valiant efforts, was
unable to get toToronto because of fog atToronto Airport.
The group hopes to have an opportunity to hear her talk at
another time.
NCIC-CTG INVESTIGATIONAL NEW DRUG
PROGRAM
Elizabeth Eisenhauer,Kingston
Dr Eisenhauer described the NCIC-CTG IND program
goals and history, and reviewed the activity of the Sarcoma
Disease Site Committee during the 1980s/1990s,including
studies of mitoxantrone, trimetrexate, 10-EDAM, topo-
tecan and docetaxel. She emphasized that the way of the
future is novel targeted agents and that the rationale for
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abnormalities of sarcomas. An example of a target is the
Philadelphia chromosome in CML in which a t(9:22)trans-
location creates Bcl-Abl.The protein product of this trans-
location is a tyrosine kinase which is of fundamental
importance in inducing malignancy. ST1 571 is an oral
inhibitor of Bcl-Abl tyrosine kinase and causes a dose-
relatedresponse in CML.Severalsarcomas,suchas Ewing’s,
rhabdomyosarcoma, myxoid liposarcoma, clear cell
sarcoma, and synovial sarcoma, show speci® c transloca-
tions. Given their rarity it will be a challenge to develop
designer drugs for sarcomas alone as it would not be a
worthwhile ® nancial investment for pharmaceutical
companies.An alternativewould be to targetgeneralsignal-
ling pathway abnormalities such as HER2/neu or molecular
alterations such as mutations of p53, cyclin dependent
kinases, and MDM2.She closed by discussing the rationale
for studying GI checkpoint arrest compounds such as
¯ avopiridol, which is about to enter phase II study by the
NCIC-CTG/CSG.
BIOLOGICAL THERAPIES IN
NEUROFIBROMATOSIS-1 ASSOCIATED
TUMORS
Ab Guha,Toronto
Dr Guha commented that neuro® bromatosis-1 is the most
commoninheritedgeneticabnormality predisposing tocancer
inhumans.NF-1 associatedperipheral nerve tumorsincludes
large plexiform neuro® bromas with a 3-5% incidence of
malignant conversion to a neuro® brosarcoma. NF-1 occurs
in 1/4000livebirths and isautosomaldominantlytransmitted
with 100% penetrance, but variable and non-predictable
expression. Half of the cases do not have a positive family
history, representing de-novo germline mutations.The NF-1
gene is carried on chromosome 17, with one of the main
functionsof theencodedproteinneuro® broministoinactivate
ras,a major signalingmolecule.Therapiesaimed at inhibiting
ras activity are therefore underinvestigation,withagentssuch
as farnesyl-transferase inhibitors (FTI).In addition, neuro® -
bromas and neuro® brosarcomas are very well vascularized,
with increased expression of the angiogenic growth factor
Vascular EndothelialGrowthFactor(VEGF).Smallmolecule
inhibitors of the VEGF receptor,such as SU5416 (SUGEN
Inc), have been demonstrated to be efficacious in inhibiting
overall growth of human NF-1 neuro® brosarcomas in
xenograft models,and similar anti-angiogenic strategies may
be useful in this metastasizing malignant tumor. Of interest,
FTIsnot only decreaseproliferation of transformed cells,but
also decrease VEGF secretion, hence may have mitogenic
and anti-angiogenicactivitiesinsolid tumorssuch as neuro® -
brosarcomas.
AGGRESSIVE FIBROMATOSIS: LESSONS
FROM DEVELOPMENTAL BIOLOGY AND
IMPLICATIONS FORTREATMENT
Ben Alman,Toronto
Dr Alman noted that aggressive ® bromatosis had been
associated with trisomy 3, trisomy 7 and deletion of the
long arm of chromosome 5. It is associated with familial
adenomatous polyposis coli, which also shows deletion of
the long arm of chromosome 5. He described some of his
studies of beta-catenin, which is a gene needed for the
development of the wings of the drosophilia. In the human
beta-catenin binds to cadherin.These studies have shown
increased expression of both beta-catenin and COX-2 in
® bromatosis. Various COX-2 inhibitors, such as sulindac,
indomethacinand MercDFUdo lead to decreasedprolifera-
tion of cultures of aggressive ® bromatosis, but also normal
® broblasts, and therefore the drugs are not selective.
PANEL DISCUSSION WITH AUDIENCE
PARTICIPATION
The initial part of the discussion focused on whether it
would be possible to develop drugs that are speci® c for
sarcomas or whether it is more likely that drugs developed
for other tumors would be tested in sarcomas. It was agreed
that the latter is more likely and that even compounds that
may target speci® c points in the cell cycle could have more
wide ranging effects. DrWong questioned the possibility of
combination chemotherapy using novel agents. Dr Eisen-
hauer felt that this would be difficult until each of these
agents had been properly evaluated. She felt there was
more potential for combinations of novel agents with
standard chemotherapy agents.
There was some discussion around the importance of
rapid recruitment of patients to phase II trials in Canada
and agreementthat aWeb site to advertise studies would be
useful. In response to a question about availability of
compounds in Europe,Will Steward outlined the bene® ts
of the Cancer Research Campaign (CRC) formulation unit
that had been developed in the UK. Elizabeth Eisenhauer
commentedthat therewas an Ontario translational research
group that was looking into the possibility of liaisions with
the CRC formulation unit. Dr Eisenhauer once again
emphasized that there are many selectively targetted agents
but it is important to identify molecular targets in STS.
There was further discussion around the difficulties of
obtaining interesting compounds, as most of these are now
controlled by major pharmaceutical companies more
interested in evaluating them in common tumor types.
SESSION 3
OPPORTUNITIESTO IMPROVETHE
THERAPEUTIC RATIO OF
LOCOREGIONAL MANAGEMENT IN
EXTREMITY AND RETROPERITONEAL
SOFTTISSUE SARCOMAS
MODERATOR: ROBERT BELL
WHO NEEDS RADIOTHERAPY AFTER
RESECTION? EXPERIENCE OF THE
SCANDINAVIAN SARCOMA GROUP
Henrik Bauer,Stockholm,Sweden
Dr Bauer addressed this topic by using features of Scandi-
navian sarcoma care, results from databases and previous
studies, results from the Scandinavian Sarcoma Group
(SSG) register,a review of the consequences of local recur-
rence, and of the local recurrence rates dependent on site
and grade. He concluded that local recurrence is strongly
associated with metastases, but is seldom the cause, and
survival will not be increased by improvements in local
treatment.Historically approximately 20% of patients were
given radiotherapy but there has been an increaed use of
radiotherapy within the SSG during the last couple of years.
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speci® cally 1) subcutaneous lesion if recurrence might lead
to amputation (arm, lower leg, foot), 2) low-grade, deep
lesions after marginal margins, 3) high-grade, deep lesions
after marginal or wide margins.In contrast he feltthat certain
groups did not needradiotherapy:1) subcutaneouslesionsof
trunkandthigh,2)low-grade,deeplesionsafterwide margins,
3) high-grade, deep lesions after compartmental margin. He
suggestedthat the consequencesof thiswould be that 60%of
all STS patients would have radiotherapy and local recur-
rence rate might drop from 20% to 10%. He posed the
question as to whether the gain in local controlwas worth the
cost and morbidity of radiotherapy.
RADIATION DOSE/SCHEDULING ISSUES
Martin Robinson,Sheffield, UK
Dr Robinson agreed with Dr Bauer that local recurrence
has littleimpacton survival,as recurrenceisprobably related
to bad biology. He provided an overview of the various
techniques in radiotherapy, including conformal
radiotherapy, brachytherapy, intraoperative radiotherapy,
neutron therapy, limb perfusion with radiotherapy, preop-
erative vs postoperative treatment,hyperfractionation,dose
issues, re-irradiation and planning IMRT.
LOCOREGIONAL CONTROL - CANADIAN
(NCIC-CTG SR2) ANDTORONTO
EXPERIENCE
Brian O’Sullivan,Toronto
In the CSG SR2 study, 190 adult patients were randomized
in a phase III trial comparing preoperative and postoperative
radiotherapy in extremity STS.The key result was that the
wound healing complications were signi® cantly higher in the
group receiving preoperative radiotherapy (31/88 patients,
35%)comparedtopostoperativeradiotherapy(16/94patients,
17% - p=0.01). A retrospective study at Princess Margaret
Hospital (PMH),showed that the sequencingof radiotherapy
in¯ uencedtheradiation® eldsize.Asimilar analysis of patients
entered on SR2 showed that the ® eld size was 50% greater
for those receivingpostoperative radiotherapy,and therewere
differences in the exposure of joints to radiotherapy between
the preoperative and postoperative groups. Dr O’Sullivan
also describedaretrospectivestudyusing existingPMHdata-
bases,from 1975to 1996,to determinewhetherlocal control
and the use of adjuvant chemotherapy in¯ uenced distant
recurrence and survival.Two groups were de® ned - a recent
era where the treatment was structured but without
chemotherapy (386 patients), and a previous era in which
treatment was less structured but included adjuvant
chemotherapy (206 patients).The endpoint was metastasis
free survival (MFS).A much higher rate of local control was
shown in the later era group (p=0.0001)but no difference in
MFS (p=0.56).Interestingly,in multivariate analysis, the use
of adjuvant chemotherapy was associated with a signi® cantly
betterMFSand theachievementof local controlhada similar
effect, when the in¯ uence of all variables was controlled for
in the prognostic model for the whole 20 year cohort.
FUNCTIONAL AND QUALITY OF LIFE
OUTCOMES IN SOFTTISSUE SARCOMA
Aileen Davis - given by Bob Bell,Toronto
This paper described preliminary results from the SR2
study using two functional outcome scales (MSTS and
TESS) and a generic health status measure (SF36).Within
the trial more than 90% of patients completed assessments
at all time points.The general ® ndings were that functional
outcomes were decreased at randomization,and functional
outcome/quality of life declined until about12 weekspostsurgery
but returned to near normal by one year. The TESS and
MSTS scores were lower at six weeks post surgery for the
preoperative radiotherapy group. If the patient experienced
wound healing complications, regardless of their treatment
group, there were detrimental effects in all scores lasting to
one year, and it affected the quality of life. The general
interpretation of these data was that it was important to
select the radiotherapy based on local anatomic factors.
NEW STRATEGIES IN THE MANAGEMENT
OF RETROPERITONEAL SARCOMAS
Carol Swallow,Toronto
Dr Swallow reviewed some of the problems arising when
treating retroperitoneal sarcomas. She then went on to
describe aToronto study involving preoperative radiotherapy
followed by radical resection±brachytherapy.Patientswith
primary or recurrent retroperitoneal tumors, without
metastasis, that were felt to be resectable, were included.
Of 56 patients screened in 31¤ 2 years 39 were entered.Most
of them were liposarcomas, and 50% were high-grade. 29
underwent total resection with many radical resections
performed. 26 received preoperative radiotherapy, and 21
brachytherapy. Late toxicity was acceptable, with one peri-
operative death. However, an unexpected complication of
acuteduodenitissuggestedthat brachytherapy was not suit-
able for the upper abdomen.Three year survival was 60%.
SURGICAL MARGINS: PAST, PRESENT
AND FUTURE
RobertTurcotte,Montreal
DrTurcotte started with a discussion of the historical de® ni-
tions of margins and pointed out the lack of consensus of
what constitutes a wide margin. A 2 cm of normal tissue
surrounding the tumor is generally called wide by surgeons
whereas pathologists would more readily call wide a margin
of 1 cm.With the more routine use of radiation therapy in
STS, studies have reported that margin either positive or
negative is the important factor affecting local recurrence
rate. Stokle has reported on a consensus between patholo-
gists and surgeons that has resulted in R0:negative margin,
R1: micro-positive margin, and R2: macroscopic residual.
He also discussed the issue of avoiding biopsy as proposed
by the Scandinavian Sarcoma Group but felt that, without
a well designed study, the medicolegal issues were too
important in North America to perform an extensive
procedure without a con® rmed diagnosis, and that neoad-
juvant treatments could not be used with this approach. He
suggested new directions which included MRI assessment
of local invasiveness of the tumor and evaluation of the
response to neoadjuvant treatments,betteridenti® cation of
metastatic patient with PET-scans and molecular probes,
better understanding of tumor behavior through cytoge-
netics and molecular biopsy and the use of adjuvant treat-
ments that might reduce the need for large margins.
PANEL DISCUSSION WITH AUDIENCE
PARTICIPATION
Questions focused around whether the size of the margin
mattered. Dr O’Sullivan felt that this was less important
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discussed.Dr Bell felt that there was no clear evidence that
® ne needle biopsy increased local recurrence rate. Dr
Swallow commented that for the retroperitoneal tumors
open biopsy sometimes did not achieve a diagnosis because
the ideal area was not necessarily biopsied, whereas under
radiologic control it might be possible to take a biopsy from
a more appropriate area.With respect to margins, Dr Bell
felt that information was lost if margins were de® ned as
positive or negative. He emphasized the need to measure
margins.There was some discussion around the difficulties
of grading tumors, and in using this information, because
of the heterogeneity of tumors. In general, it was felt that
high-grade tumors were more prone to local recurrence
and most of these should receive radiotherapy, although
other factors should also be taken into consideration.
SESSION 4
FUTURE OFTHE CANADIAN SARCOMA
GROUP
INTERDISCIPLINARY HEALTH
RESEARCH TEAM IN MUSCULOSKELETAL
NEOPLASIA
Robert Bell,Toronto
Dr Bell described a Letter of Intent that he had submitted,
as team leader, to a new federal program that offers grants
for Interdisciplinary Health Research Teams (IHRT). If
funded, this team would involve three main centres -
Toronto, Vancouver and Montreal - with several investiga-
tors from each centre. It would also have as a core the
facilities of the Canadian Sarcoma Group tumor bank and
database, as well as local databases. It would focus on four
projects - molecular pro® les of sarcoma using micro-array
technology, developmental pathways in sarcoma, radiation
effects on ® broblast function, and disability evaluation in
sarcoma treatment.
RELATIONSHIP OF CSG WITH SARCOMA
DISEASE SITE COMMITTEE OF NCIC-CTG
Elizabeth Eisenhauer,Kingston
Dr Eisenhauer reviewed the mandate and structure of
NCIC-CTG. She described the selection of disease site
committees, their chairs and executives.She then outlined
the procedures necessary for development of phase II and
III clinical trials through the ClinicalTrials Group.
CANADIAN SARCOMA GROUP -WHERE
ARE WE GOING?
Vivien Bramwell,London,UK
Dr Bramwell brie¯ y reviewed the history and activities of
the CSG, which was formed in 1985 as a multidisciplinary
group with the aims to conduct, develop, coordinate and
stimulate research in the ® eld of sarcomas. The Canadian
Soft Tissue Sarcoma Tumor Bank/Correlative Clinical
Database has accrued tumors from 712 patients for a total
of 810 tumors in a seven year period. She then presented
analysis of how well the CSG group had addressed the
various aims. The objective of planning and executing
clinical research studies had been addressed by several
NCIC-CTG/CSG phase II and III clinical trials in adult
STS. The aim of promoting experimental studies in the
etiology,diagnosis,pathogenesis and evolutionof sarcomas,
has been addressed indirectly, in facilitating interactions
between various scientists and establishing the tumor bank/
database. The third aim, to develop standard criteria for
assigning histological subtype and grade and to assess and
apply new research techniques to the classi® cation of
sarcomas,has not beenaddressed,mainly because of limited
resources. The fourth aim was, in each of the main
therapeuticareas, to develop guidelinesfor optimal manage-
ment. Although the results of a survey of current practice
was published in 1988, and a symposium was held at the
Royal College of Physicians and Surgeons of Canada also
in 1988, much of the recent activity with respect to
guidelines is focused on a provincial basis through Cancer
Care Ontario Practice GuidelinesInitiative SarcomaGroup,
and also guidelines developed in British Columbia. The
® fth aim of collaboration, liaison with other multicentre
cooperative groups and remaining informed about current
international research had been ful® lled by regular attend-
ance of Executive Committee members at meetings of the
Connective Tissue Oncology Society (CTOS), the Inter-
group initiative of the National Cancer Institute. Also, the
CSG has performed Intergroup studies with the European
Osteosarcoma Intergroup and the EORTC.
Looking to the future, Dr Bramwell posed the following
questions:
1. Does the current structure facilitate input from
members?
2. Does the structure cover the diverse interestsin sarcoma
and development of ideas/projects?
3. Does the structure allow us to move in new directions?
She suggested there might be some options regarding the
structure of the CSG. She compared the bene® ts and
problems of each structure.
1. Maintain the current structure and activities
2. Dues paying/professional association (similar to CTOS)
3. Further harmonize with NCIC-CTG Sarcoma Disease
Site Group
DISCUSSION
There was very little enthusiasm for a move to a dues
paying organization modelled on CTOS. The number of
sarcoma specialists is too small to make this a realistic
proposition. Dr Bell felt that over the years there had been
a natural evolution of the CSG structure and functions and
that the group is addressing many of the important issues.
There was a prolonged discussion about the number of
meetings that might be held by the CSG, how these might
be funded, and what the content might be. Some of the
clinicians favoured educational review sessions but others
felt that this might be better done at other meetings,
particularly the CTOS meetings which have a strong
educationalcomponent.However,concernswere expressed
about the expense and difficulty of getting to many of these
meetings.Therewas some concernabout the lackof regional
infrastructure of the CSG and about communications. A
number of suggestionsincludedthe importanceof develop-
ment of a Web page and also a more structured planning
function for trial development. Dr Eisenhauer suggested
that, like other disease site committees of NCIC-CTG, it
would be important to have small subgroups of 2-3 people
to work up ideas for possible studies. Discussion among
these groups could take place by email. Three suggested
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molecular studies, systemic treatment.
The importance of capturing as much data as possible
from the Canadian sarcoma population was emphasized.
Dr Bell felt that if the IHRT was funded it could do some
of this data work. There were questions as to whether it
would be possible to make the IHRT inclusive of all centres.
Dr Bell felt that clinical data collection component might
provide the opportunity for multicentre involvement. He
gave an example of a giant cell bone tumor study involving
ten centres across Canada. Dr Eisenhauer emphasized the
importance of using the data from the 700 patients in the
CSG soft tissue sarcoma database to generate ideas for
trials, and suggested that the CSG might take a lead
internationally on Intergroup trials.The American College
of Surgeonsis developing a ® bromatosis trial and Elizabeth
Eisenhauer suggested that this should be proposed as an
Intergroup study to NCIC-CTG. There was a proposal
that the CSG be more involved in clinical management
standards and guidelines.Dr Bramwell expressedreluctance
about getting into this area because there are already
provincial initiatives whichare betterfunded.Dr.Rajaraman
suggested that the CSG might examine and review the
Ontario guidelinesand perhaps endorseand distributethese
to the rest of the country.Dr Bramwell stated that if a CSG
web site was established, a link to the Ontario Practice
Guidelines Initiative might be the most practical. There
was asuggestionthat the CSGmightbe indirectlyinvolved in
education and that this could be done by small group meet-
ings at venues such as the NCIC-CTG meeting. Research
ideas might come out of smaller meetings with a focused
agenda.Dr Bell asked how people were funded to attend the
NCIC-CTG meeting and Dr Eisenhauer commented that
this was generallyby office, ie. site chairs, principal investiga-
tors,trial committeemembers,and by invitation,the number
of which given to any one centre depended on the numbers
of patients entered onto clinical trials.
The meeting was concluded. Dr Bramwell will write a
report to be submitted to the CSG Executive for the
NCIC-CTG meeting on 17 April 2000.
Vivien H.C. Bramwell
PhD, MB, BS, FRCP
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